We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights WCLD, XBI, IGV, ITB, and IWP
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 17, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: WisdomTree Cloud Computing Fund (WCLD - Free Report) , SPDR S&P Biotech ETF (XBI - Free Report) , iShares Expanded Tech-Software Sector ETF (IGV - Free Report) , iShares U.S. Home Construction ETF (ITB - Free Report) , and iShares Russell Mid-Cap Growth ETF (IWP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
5 Top-Ranked ETFs on Sale
Wall Street is seeing tumultuous trading this year, with the major bourses in deep red so far. A war in Ukraine coupled with Fed rate hike bets and inflationary pressures has led to huge volatility and uncertainty in the stock market. Notably, the S&P 500 is down 10.6% year to date.
According to John Hancock Investment Management Co-Chief Investment Strategist Emily Roland, U.S. stocks are currently on sale, compelling investors to buy on the dip. As such, we have highlighted five ETFs from different zones that have plunged the most this year but have a solid Zacks ETF Rank #1 (Strong Buy) or 2 (Buy).
These products are poised to outperform in the coming weeks when the market resumes its uptrend.
Inside the Bull Thesis
The S&P 500 is attractively valued at the current levels. This is especially true as the index is currently trading with a P/E ratio of 24.31 versus 26.08 at the start of the year and 35.96 at the start of 2021. This makes the stocks tempting to investors.
Though the abrupt rise in commodity prices and the aftermath of the Russia-Ukraine war have led to concerns about a global economic slowdown, consumer spending remains strong given the elevated wage growth and lower unemployment rate.
The Fed is expected to raise interest rates by 25 bps in the FOMC meeting. Powell is betting that the economy can withstand modestly higher borrowing costs with a low unemployment rate and solid consumer spending. The initial phase of the rate increase will be good for stocks as it will reflect an improving economy.
On the other hand, Ukraine and Russia are in peace talks, which seems more realistic now. The agreement will end the war, giving a boost to the stocks (read: 4 Sector ETFs to Win From Fed Rate Hike).
We have highlighted the ETFs in detail below:
WisdomTree Cloud Computing Fund – Down 33.3%
WisdomTree Cloud Computing Fund offers exposure to emerging and fast-growing U.S.-listed companies (including ADRs) that are primarily focused on cloud software and services, and follows the BVP Nasdaq Emerging Cloud Index. It holds 76 stocks in its basket and charges investors 45 bps in fees per year.
SPDR S&P Biotech ETF offers equal-weight exposure across 189 biotechnology stocks. It follows the S&P Biotechnology Select Industry Index, charging investors 35 bps in annual fees.
SPDR S&P Biotech ETF has AUM of $6.6 billion and trades in an average daily volume of 14.2 million shares. XBI has a Zacks ETF Rank #2.
iShares Expanded Tech-Software Sector ETF – Down 22.1%
iShares Expanded Tech-Software Sector ETF provides exposure to software companies in the technology and communication services sectors by tracking the S&P North American Expanded Technology Software Index. The fund holds a basket of 127 securities.
iShares Expanded Tech-Software Sector ETF is popular with AUM of $5.9 billion. Volume is good as it exchanges 1.8 million shares a day. The product charges 43 bps in annual fees and has a Zacks ETF Rank #2.
iShares U.S. Home Construction ETF – Down 21.8%
iShares U.S. Home Construction ETF provides exposure to U.S. companies that manufacture residential homes by tracking the Dow Jones U.S. Select Home Construction Index. With AUM of $2 billion, it holds a basket of 46 stocks with heavy concentration on the top two firms.
iShares U.S. Home Construction ETF charges 41 bps in annual fees and trades in a heavy volume of around 5 million shares a day on average. iShares U.S. Home Construction ETF has a Zacks ETF Rank #2 (read: Housing ETFs Likely to Spring Up in the Key Selling Season).
iShares Russell Mid-Cap Growth ETF – Down 20.4%
With AUM of $12.5 billion, iShares Russell Mid-Cap Growth ETF offers exposure to mid-sized U.S. companies whose earnings are expected to grow at an above-average rate relative to the market by tracking the Russell MidCap Growth Index. It holds 389 securities in its basket, with none accounting for more than 1.6% of the total assets.
iShares Russell Mid-Cap Growth ETF charges 23 bps in annual fees and trades in an average daily volume of 1.3 million shares. The product has a Zacks ETF Rank #2.
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights WCLD, XBI, IGV, ITB, and IWP
For Immediate Release
Chicago, IL – March 17, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: WisdomTree Cloud Computing Fund (WCLD - Free Report) , SPDR S&P Biotech ETF (XBI - Free Report) , iShares Expanded Tech-Software Sector ETF (IGV - Free Report) , iShares U.S. Home Construction ETF (ITB - Free Report) , and iShares Russell Mid-Cap Growth ETF (IWP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
5 Top-Ranked ETFs on Sale
Wall Street is seeing tumultuous trading this year, with the major bourses in deep red so far. A war in Ukraine coupled with Fed rate hike bets and inflationary pressures has led to huge volatility and uncertainty in the stock market. Notably, the S&P 500 is down 10.6% year to date.
According to John Hancock Investment Management Co-Chief Investment Strategist Emily Roland, U.S. stocks are currently on sale, compelling investors to buy on the dip. As such, we have highlighted five ETFs from different zones that have plunged the most this year but have a solid Zacks ETF Rank #1 (Strong Buy) or 2 (Buy).
These products are poised to outperform in the coming weeks when the market resumes its uptrend.
Inside the Bull Thesis
The S&P 500 is attractively valued at the current levels. This is especially true as the index is currently trading with a P/E ratio of 24.31 versus 26.08 at the start of the year and 35.96 at the start of 2021. This makes the stocks tempting to investors.
Though the abrupt rise in commodity prices and the aftermath of the Russia-Ukraine war have led to concerns about a global economic slowdown, consumer spending remains strong given the elevated wage growth and lower unemployment rate.
The Fed is expected to raise interest rates by 25 bps in the FOMC meeting. Powell is betting that the economy can withstand modestly higher borrowing costs with a low unemployment rate and solid consumer spending. The initial phase of the rate increase will be good for stocks as it will reflect an improving economy.
On the other hand, Ukraine and Russia are in peace talks, which seems more realistic now. The agreement will end the war, giving a boost to the stocks (read: 4 Sector ETFs to Win From Fed Rate Hike).
We have highlighted the ETFs in detail below:
WisdomTree Cloud Computing Fund – Down 33.3%
WisdomTree Cloud Computing Fund offers exposure to emerging and fast-growing U.S.-listed companies (including ADRs) that are primarily focused on cloud software and services, and follows the BVP Nasdaq Emerging Cloud Index. It holds 76 stocks in its basket and charges investors 45 bps in fees per year.
WisdomTree Cloud Computing Fund has amassed $737.2 million in its asset base and trades in an average daily volume of 605,000 shares. It has a Zacks ETF Rank #2 (read: Bet on Top-Ranked Tech ETFs to Ride the Recent Rebound Rally).
SPDR S&P Biotech ETF – Down 26.5%
SPDR S&P Biotech ETF offers equal-weight exposure across 189 biotechnology stocks. It follows the S&P Biotechnology Select Industry Index, charging investors 35 bps in annual fees.
SPDR S&P Biotech ETF has AUM of $6.6 billion and trades in an average daily volume of 14.2 million shares. XBI has a Zacks ETF Rank #2.
iShares Expanded Tech-Software Sector ETF – Down 22.1%
iShares Expanded Tech-Software Sector ETF provides exposure to software companies in the technology and communication services sectors by tracking the S&P North American Expanded Technology Software Index. The fund holds a basket of 127 securities.
iShares Expanded Tech-Software Sector ETF is popular with AUM of $5.9 billion. Volume is good as it exchanges 1.8 million shares a day. The product charges 43 bps in annual fees and has a Zacks ETF Rank #2.
iShares U.S. Home Construction ETF – Down 21.8%
iShares U.S. Home Construction ETF provides exposure to U.S. companies that manufacture residential homes by tracking the Dow Jones U.S. Select Home Construction Index. With AUM of $2 billion, it holds a basket of 46 stocks with heavy concentration on the top two firms.
iShares U.S. Home Construction ETF charges 41 bps in annual fees and trades in a heavy volume of around 5 million shares a day on average. iShares U.S. Home Construction ETF has a Zacks ETF Rank #2 (read: Housing ETFs Likely to Spring Up in the Key Selling Season).
iShares Russell Mid-Cap Growth ETF – Down 20.4%
With AUM of $12.5 billion, iShares Russell Mid-Cap Growth ETF offers exposure to mid-sized U.S. companies whose earnings are expected to grow at an above-average rate relative to the market by tracking the Russell MidCap Growth Index. It holds 389 securities in its basket, with none accounting for more than 1.6% of the total assets.
iShares Russell Mid-Cap Growth ETF charges 23 bps in annual fees and trades in an average daily volume of 1.3 million shares. The product has a Zacks ETF Rank #2.
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.